Advertisement

Les facteurs de croissance et les récepteurs à activité tyrosine kinase

  • Jacques Robert
Part of the Oncologie pratique book series (ONCOLPRAT)

Résumé

La signalisation apportée par les facteurs de croissance est certainement la mieux connue en raison, en particulier, de son rôle dans l’oncogenèse. Elle ouvre en fait sur de multiples voies de transduction que nous avons distribuées en plusieurs chapitres; celui-ci concerne exclusivement les facteurs de croissance et leurs récepteurs; les chapitres 2 et 3 présenteront les principales voies de signalisation qui sont activées en aval de l’interaction d’un facteur de croissance et d’un récepteur. Les facteurs de croissance et leurs récepteurs sont classés en fonction du mécanisme de l’activation de ces derniers: la classe principale est celle des récepteurs à activité tyrosine kinase (RTK) que nous étudierons ici, une autre classe est celle des récepteurs activant une tyrosine kinase cytoplasmique qui seront étudiés au chapitre 4, une troisième celle des récepteurs à activité sérine/thréonine kinase (chapitre 5).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliographie

  1. Acquaviva J, Wong R, Charest A. (2009) The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta; 1795: 37–52.PubMedGoogle Scholar
  2. Beenken A, Mohammadi M. (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov; 8: 235–53.PubMedCrossRefGoogle Scholar
  3. Bose R, Zhang X. (2009) The ErbB kinase domain: structural perspectives into kinase activation and inhibition. Exp Cell Res; 315: 649–58.PubMedCrossRefGoogle Scholar
  4. Brodeur GM, Minturn JE, Ho R et al. (2009) Trk receptor expression and inhibition in neuroblastomas. Clin Cancer Res; 15: 3244–50.PubMedCrossRefGoogle Scholar
  5. Burgess AW, Cho HS, Eigenbrot C et al. (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell; 12: 541–52.PubMedCrossRefGoogle Scholar
  6. Chiarle R, Voena C, Ambrogio C et al. (2008) The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer; 8: 11–23.PubMedCrossRefGoogle Scholar
  7. Ciardiello F, Tortora G. (2008) EGFR antagonists in cancer treatment. N Engl J Med; 358: 1160–74.PubMedCrossRefGoogle Scholar
  8. Citri A, Yarden Y. (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol; 7: 505–16.PubMedCrossRefGoogle Scholar
  9. Ellis LM, Hicklin DJ. (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer; 8: 579–91.PubMedCrossRefGoogle Scholar
  10. Ferguson KM. (2008) Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys; 37: 353–73.PubMedCrossRefGoogle Scholar
  11. Ferrara N. (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer; 2: 795–803.PubMedCrossRefGoogle Scholar
  12. Green JL, Kuntz SG, Sternberg PW. (2008) Ror receptor tyrosine kinases: orphans no more. Trends Cell Biol; 18: 536–44.PubMedCrossRefGoogle Scholar
  13. Harari PM, Allen GW, Bonner JA. (2007) Biology of interactions: anti-epidermal growth factor receptor agents. J Clin Oncol; 25: 4057–65.PubMedCrossRefGoogle Scholar
  14. Harper SJ, Bates DO. (2008) VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer; 8: 880–7.PubMedCrossRefGoogle Scholar
  15. Harris RC, Chung E, Coffey RJ. (2003) EGF receptor ligands. Exp Cell Res; 284: 2–13.PubMedCrossRefGoogle Scholar
  16. Holbro T, Civenni G, Hynes NE. (2003) The ErbB receptors and their role in cancer progression. Exp Cell Res; 284: 99–110.PubMedCrossRefGoogle Scholar
  17. Holbro T, Hynes NE. (2004) ErbB receptors: Directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol; 44: 195–217.PubMedCrossRefGoogle Scholar
  18. Hynes NE, Lane HA. (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer; 5: 341–54.PubMedCrossRefGoogle Scholar
  19. Jones RB, Gordus A, Krall JA, MacBeath G. (2006) A quantitative protein interaction network for the ErbB receptors using protein microarrays. Nature; 439: 168–74.PubMedCrossRefGoogle Scholar
  20. Jorissen RN, Walker F, Pouliot N et al. (2003) Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res; 284: 31–53.PubMedCrossRefGoogle Scholar
  21. Kumar A, Petri ET, Halmos B, Boggon TJ. (2008) Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol; 26: 1742–51.PubMedCrossRefGoogle Scholar
  22. Leahy DJ. (2008) A molecular view of anti-ErbB monoclonal antibody therapy. Cancer Cell; 13: 291–3.PubMedCrossRefGoogle Scholar
  23. Linger RM, Keating AK, Earp HS, Graham DK. (2008) TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res.; 100: 35–83.PubMedCrossRefGoogle Scholar
  24. Olayioye MA, Neve RM, Lane HA, Hynes NE. (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J; 19: 3159–67.PubMedCrossRefGoogle Scholar
  25. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. (2006) VEGF receptor signalling — in control of vascular function. Nat Rev Mol Cell Biol; 7: 359–71.PubMedCrossRefGoogle Scholar
  26. Pollak M. (2008) Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer; 8: 915–28.PubMedCrossRefGoogle Scholar
  27. Schlessinger J. (2002) Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell; 110: 669–72.PubMedCrossRefGoogle Scholar
  28. Schneider MR, Wolf E. (2009) The epidermal growth factor receptor ligands at a glance. J Cell Physiol; 218: 460–6.PubMedCrossRefGoogle Scholar
  29. Sequist LV, Lynch TJ. (2008) EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med; 59: 429–42.PubMedCrossRefGoogle Scholar
  30. Sorkin A, Goh LK. (2009) Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res; 315: 683–96.PubMedCrossRefGoogle Scholar
  31. Weiner HL, Zagzag D. (2000) Growth factor receptor tyrosine kinases: cell adhesion kinase family suggests a novel signaling mechanism in cancer. Cancer Invest; 18: 544–54.PubMedCrossRefGoogle Scholar
  32. Wilson KJ, Gilmore JL, Foley J et al. (2009) Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther; 122: 1–8.PubMedCrossRefGoogle Scholar
  33. Wykosky J, Debinski W. (2008) The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res; 6: 1795–806.PubMedCrossRefGoogle Scholar
  34. Yarden Y, Sliwkowski MX. (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol; 2: 127–37.PubMedCrossRefGoogle Scholar
  35. Zhang X, Gureasko J, Shen K et al. (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006; 125: 1137–49.Google Scholar

Copyright information

© Springer-Verlag France, Paris 2010

Authors and Affiliations

  • Jacques Robert
    • 1
  1. 1.Université Victor Segalen Bordeaux 2Institut BergoniéBordeaux Cedex

Personalised recommendations